Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
This study has been completed.
Information provided by (Responsible Party):
First received: September 20, 2007
Last updated: September 18, 2013
Last verified: September 2013
The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model|
Resource links provided by NLM:
Drug Information available for: Epinastine Epinastine hydrochloride Olopatadine Olopatadine hydrochlorideU.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- Change in Ocular Itch Score From Baseline [ Time Frame: 0 hours, 12 hours ] [ Designated as safety issue: No ]Ocular itch was measured on a 0 (none) to 4 (severe itch with continual desire to rub eyes) scale. Negative values for change from baseline represent favorable outcomes.
Secondary Outcome Measures:
- Ocular Comfort Score at 12 Hours [ Time Frame: 12 hours ] [ Designated as safety issue: No ]Ocular comfort was measured on a 0 (more uncomfortable) to 10 (more comfortable) scale.
|Study Start Date:||October 2007|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Elestat BID for 2 days
|Active Comparator: Pataday||
Pataday QD for 2 days
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00534794
|United States, Massachusetts|
|Ophthalmic Consultants of Boston|
|Boston, Massachusetts, United States, 02114|
Sponsors and Collaborators
|Principal Investigator:||Michael Raizman, MD||Ophthalmic Consultants of Boston|